2/6
After reviewer feedback, we boosted activity and hit rate. Keeping the same active‑site design, we improved solubility and expression via surface redesign, yielding KempTIM1, one of the most active first‑round de novo enzymes reported to date (kcat/KM = 21,000 M⁻¹ s⁻¹).